Montis’ mission is to therapeutically exploit cellular interactions between perivascular macrophages and tumor vasculature to drive and sustain immune reactions against solid tumors.
Location: Belgium, Flemish Brabant, Meise
Employees: 1-10
Total raised: $9.14M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | ALSA Ventu... | alsaventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.02.2020 | Seed | $9.14M | - |
Mentions in press and media 3
| Date | Title | Description |
| 14.06.2021 | Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics | Leuven, Belgium, 14 June 2021 -Montis Biosciences, a Belgium-based biotech company focused on the development of novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, anno... |
| 29.09.2020 | Dr. Karen Zinkewich-Péotti brings brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech | LEUVEN, BELGIUM, EINPresswire.com -- MONTIS BIOSCIENCES, a discovery stage biotech company focused on novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, has named Karen ... |
| 20.02.2020 | Montis Biosciences launched with â¬8,4 million seed financing and a novel approach to immune-oncology | Montis was founded by Droia Ventures, VIB and KU Leuven based on the foundational science discovered by the labs of Peter Carmeliet (VIB-KU Leuven) and Massimiliano Mazzone (VIB-KU Leuven). For the seed financing, the founders were joined b... |